vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and NICOLET BANKSHARES INC (NIC). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $104.0M, roughly 1.8× NICOLET BANKSHARES INC). NICOLET BANKSHARES INC runs the higher net margin — 38.8% vs 13.3%, a 25.4% gap on every dollar of revenue. On growth, NICOLET BANKSHARES INC posted the faster year-over-year revenue change (12.5% vs -1.8%). NICOLET BANKSHARES INC produced more free cash flow last quarter ($149.4M vs $24.6M). Over the past eight quarters, NICOLET BANKSHARES INC's revenue compounded faster (12.5% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
AMPH vs NIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $104.0M |
| Net Profit | $24.4M | $40.3M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 48.3% |
| Net Margin | 13.3% | 38.8% |
| Revenue YoY | -1.8% | 12.5% |
| Net Profit YoY | -35.7% | 16.9% |
| EPS (diluted) | $0.51 | $2.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $104.0M | ||
| Q3 25 | $191.8M | $102.9M | ||
| Q2 25 | $174.4M | $95.7M | ||
| Q1 25 | $170.5M | $89.4M | ||
| Q4 24 | $186.5M | $92.4M | ||
| Q3 24 | $191.2M | $90.7M | ||
| Q2 24 | $182.4M | $85.0M | ||
| Q1 24 | $171.8M | $82.2M |
| Q4 25 | $24.4M | $40.3M | ||
| Q3 25 | $17.4M | $41.7M | ||
| Q2 25 | $31.0M | $36.0M | ||
| Q1 25 | $25.3M | $32.6M | ||
| Q4 24 | $38.0M | $34.5M | ||
| Q3 24 | $40.4M | $32.5M | ||
| Q2 24 | $37.9M | $29.3M | ||
| Q1 24 | $43.2M | $27.8M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 48.3% | ||
| Q3 25 | 13.2% | 50.4% | ||
| Q2 25 | 24.2% | 46.8% | ||
| Q1 25 | 21.9% | 44.9% | ||
| Q4 24 | 24.2% | 46.8% | ||
| Q3 24 | 29.8% | 45.0% | ||
| Q2 24 | 30.3% | 43.3% | ||
| Q1 24 | 27.9% | 41.8% |
| Q4 25 | 13.3% | 38.8% | ||
| Q3 25 | 9.0% | 40.6% | ||
| Q2 25 | 17.8% | 37.6% | ||
| Q1 25 | 14.8% | 36.4% | ||
| Q4 24 | 20.4% | 37.3% | ||
| Q3 24 | 21.1% | 35.8% | ||
| Q2 24 | 20.8% | 34.5% | ||
| Q1 24 | 25.1% | 33.8% |
| Q4 25 | $0.51 | $2.63 | ||
| Q3 25 | $0.37 | $2.73 | ||
| Q2 25 | $0.64 | $2.34 | ||
| Q1 25 | $0.51 | $2.08 | ||
| Q4 24 | $0.74 | $2.21 | ||
| Q3 24 | $0.78 | $2.10 | ||
| Q2 24 | $0.73 | $1.92 | ||
| Q1 24 | $0.81 | $1.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $134.9M |
| Stockholders' EquityBook value | $788.8M | $1.3B |
| Total Assets | $1.6B | $9.2B |
| Debt / EquityLower = less leverage | 0.77× | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | $134.9M | ||
| Q3 25 | $608.6M | $134.6M | ||
| Q2 25 | $607.7M | $134.3M | ||
| Q1 25 | $603.9M | $156.6M | ||
| Q4 24 | $601.6M | $161.4M | ||
| Q3 24 | $596.4M | $161.2M | ||
| Q2 24 | $586.9M | $162.4M | ||
| Q1 24 | $594.0M | $162.3M |
| Q4 25 | $788.8M | $1.3B | ||
| Q3 25 | $776.7M | $1.2B | ||
| Q2 25 | $757.5M | $1.2B | ||
| Q1 25 | $751.3M | $1.2B | ||
| Q4 24 | $732.3M | $1.2B | ||
| Q3 24 | $727.7M | $1.1B | ||
| Q2 24 | $713.3M | $1.1B | ||
| Q1 24 | $672.4M | $1.1B |
| Q4 25 | $1.6B | $9.2B | ||
| Q3 25 | $1.7B | $9.0B | ||
| Q2 25 | $1.6B | $8.9B | ||
| Q1 25 | $1.6B | $9.0B | ||
| Q4 24 | $1.6B | $8.8B | ||
| Q3 24 | $1.5B | $8.6B | ||
| Q2 24 | $1.5B | $8.6B | ||
| Q1 24 | $1.6B | $8.4B |
| Q4 25 | 0.77× | 0.11× | ||
| Q3 25 | 0.78× | 0.11× | ||
| Q2 25 | 0.80× | 0.11× | ||
| Q1 25 | 0.80× | 0.13× | ||
| Q4 24 | 0.82× | 0.14× | ||
| Q3 24 | 0.82× | 0.14× | ||
| Q2 24 | 0.82× | 0.15× | ||
| Q1 24 | 0.88× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $153.5M |
| Free Cash FlowOCF − Capex | $24.6M | $149.4M |
| FCF MarginFCF / Revenue | 13.4% | 143.7% |
| Capex IntensityCapex / Revenue | 4.5% | 3.9% |
| Cash ConversionOCF / Net Profit | 1.35× | 3.81× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $275.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $153.5M | ||
| Q3 25 | $52.6M | $45.9M | ||
| Q2 25 | $35.6M | $38.9M | ||
| Q1 25 | $35.1M | $41.8M | ||
| Q4 24 | $29.0M | $133.7M | ||
| Q3 24 | $60.0M | $39.6M | ||
| Q2 24 | $69.1M | $37.3M | ||
| Q1 24 | $55.3M | $23.4M |
| Q4 25 | $24.6M | $149.4M | ||
| Q3 25 | $47.2M | $45.9M | ||
| Q2 25 | $25.0M | $38.4M | ||
| Q1 25 | $24.4M | $41.3M | ||
| Q4 24 | $16.6M | $116.8M | ||
| Q3 24 | $46.2M | $34.7M | ||
| Q2 24 | $63.1M | $34.4M | ||
| Q1 24 | $46.5M | $20.1M |
| Q4 25 | 13.4% | 143.7% | ||
| Q3 25 | 24.6% | 44.6% | ||
| Q2 25 | 14.3% | 40.1% | ||
| Q1 25 | 14.3% | 46.2% | ||
| Q4 24 | 8.9% | 126.4% | ||
| Q3 24 | 24.1% | 38.3% | ||
| Q2 24 | 34.6% | 40.5% | ||
| Q1 24 | 27.1% | 24.4% |
| Q4 25 | 4.5% | 3.9% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 6.3% | 0.5% | ||
| Q4 24 | 6.7% | 18.3% | ||
| Q3 24 | 7.2% | 5.4% | ||
| Q2 24 | 3.3% | 3.5% | ||
| Q1 24 | 5.1% | 4.0% |
| Q4 25 | 1.35× | 3.81× | ||
| Q3 25 | 3.03× | 1.10× | ||
| Q2 25 | 1.15× | 1.08× | ||
| Q1 25 | 1.39× | 1.28× | ||
| Q4 24 | 0.76× | 3.88× | ||
| Q3 24 | 1.48× | 1.22× | ||
| Q2 24 | 1.82× | 1.28× | ||
| Q1 24 | 1.28× | 0.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
NIC
Segment breakdown not available.
